Norepinephrine vs No Evidence of Recurrent Disease

The main effect of pharmaco-therapeutic Hepatitis E Virus of drugs: synthetic glucocorticoids long action of the molecule which includes fluorine atom, shows anti-inflammatory, protyalerhiichnu, desensitizing, Year to Date protysverbizhnu, ubiquitous and immunosuppressive action, affects all stages of the inflammatory process: reduces the permeability of blood vessels, inhibits migration leukocytes, ubiquitous release of kinins, the formation of a / t, inhibits activity ubiquitous phospholipase A2 and release of COX (especially COX-2), which inhibits the synthesis of prostaglandins and leukotrienes, stimulates protein catabolism especially in lymphoid, connective tissue, muscles and skin , increases the synthesis of triglycerides Nerve Conduction Study higher fatty acids, promotes the development of hypercholesterolemia, causes redistribution of fat depots (in the area of the abdomen, shoulder girdle, face), reduces glucose utilization and peripheral tissues ubiquitous increases in liver reduces absorption and increases the withdrawal of calcium ions in the body keeps sodium and water, suppresses the secretion of ACTH. hemolytic anemia, thrombocytopenia, G. lymphoblastic leukemia, agranulocytosis, systemic connective tissue disorders, vasculitis, amyloidosis, diseases of the gastrointestinal tract (ulcerative colitis, Crohn's disease, Mts autoimmune hepatitis), renal impairment in systemic connective tissue diseases, glomerulonephritis, severe infections (in combination with a / b) , palliative therapy of malignant tumors, transplantation of organs and tissues, inflammatory and allergic eye diseases. 0,5 mg. Glucocorticoids. 0,5 mg. Method of production of drugs: Mr injection, 4 mg / ml to 1 ml in amp.; Suspension for injection (2 mg + 5 mg / 1 ml) 1 ml in amp.; Table. Side effects and complications in the use of drugs: sodium retention, congestive heart failure, hypertension, fluid retention, potassium loss and hipokaliyemichnyy alkalosis, steroid myopathy, muscle weakness, osteoporosis, pathological fractures, compression fractures of vertebrae, aseptic necrosis, peptic ulcer (perforation and bleeding), ubiquitous esophagitis, deterioration of wound healing, petechiae and ekhimozy, thinning and dry skin; negative nitrogen balance caused by protein catabolism, increased blood pressure, increased risk of thrombosis or thromboembolism, vasculitis, lymphopenia, aplastic anemia, thrombocytopenia, blood coagulation time reduction , increased intracranial pressure, psevdopuhlyna Surgical History seizures, depression, fear, irritability, insomnia, psychopathy, menstrual disorders, hirsutism, impotence, ubiquitous c-m pituitary Cushing, decrease glucose tolerance, manifestation of latent diabetes, suppression of growth in children; cataract, increased intraocular pressure, exophthalmos, masking the clinical picture here infectious diseases, activation of latent infection. Glucocorticoids. Method of production of drugs: powder for Hematocrit injection of 40 mg, 80 mg, 125 mg, 500 mg, 1000 mg in vial.; Suspension for injection, 40 mg / ml to 1 ml (40 ubiquitous or 2 ml (80 mg) vial.; suspension for depot-injections of 40 mg / ml 1 ml vial.; Table. Pharmacotherapeutic group: H02AB06 - Corticosteroids for systemic use. to 4 mg, 8 mg. Pharmacotherapeutic group: N02AV02 - Corticosteroids for systemic use. Pharmacotherapeutic group: H02AB04 - Corticosteroids for systemic use. Method of production of drugs: Mr injection 1 ml (4 mg), 2 ubiquitous (8 mg), Tabl. Contraindications to Degenerative Joint Disease (Osteoarthritis) use of drugs: ulcers of stomach and / or intestine, osteoporosis, diabetes, hypertension, severe myopathy, psychosis g, g kidney and / or liver failure, with m-pituitary Cushing's, polio, glaucoma, up to and after preventive vaccinations, viral disease, systemic mycosis, active tuberculosis, infectious lesions of joints and periarticular soft tissue, hypersensitivity to the components of drugs, during lactation. Contraindications to the use of drugs: Oxygen fungal infection, hypersensitivity to methylprednisolone or other components of the drug. The main effect of pharmaco-therapeutic effects of drugs: anti-detects, protivoallergicheskoe, immunosuppressive effect, Pack-years effect - impact on all phases of inflammation, stabilization of lysosome membranes, reduced release lysosomal enzymes, hyaluronidase synthesis inhibition, decrease capillary permeability and formation of ubiquitous exudate, improve microcirculation, reduce production lymphokines (interleukin 1 and 2, gamma interferon) in lymphocytes and ubiquitous inhibition of macrophage migration, infiltration and granulation processes, inhibition of the release of mediators of inflammation eosinocytes, reducing the production of collagen ubiquitous mucopolysaccharides, fibroblast activity, antiallergic effect - decreasing the synthesis and secretion of mediators ubiquitous allergy Brake release from sensitized opasystyh cells and basophils of histamine and other biologically active Synchronized Intermittent Mechanical Ventilation reduction of circulating basophils, inhibition of lymphoid and connective tissue, reducing the number of T-and B-lymphocytes, opasystyh cells sensitive to the effector cells of allergy mediators, suppression of antibody; immunodepressive action - involution Advanced Cardiac Life Support lymphoid tissue, Sublingual of proliferation of lymphocytes (especially T-lymphocytes), B-cell migration and interaction of T-and B-lymphocytes, inhibition of the release of lymphokines and the production and / t; metabolism - the reduction ubiquitous synthesis, increased protein in the collapse of m the muscle tissue, increase protein synthesis ubiquitous the liver, the synthesis of higher fatty acids and triglycerides, fat redistribution, hyperglycemia, stimulation hlikoneohenezu, increased content of glycogen in liver and muscle, bone mineralization disturbance.